Skip to main content

Danaher Value Stock - Dividend - Research Selection

Danaher

ISIN: US2358511028 , WKN: 866197

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company\'s Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors. Its Diagnostics segment provides chemistry, immunoassay, microbiology, and automation systems, as well as hematology and flow cytometry products. The company offers analytical instruments, reagents, consumables, software, and services for hospitals, physicians\' offices, reference laboratories, and other critical care settings. Its Dental segment provides consumables, equipment, and services to diagnose, treat, and prevent disease and ailments of the teeth, gums, and supporting bone. This segment offers implant systems, dental prosthetics, and associated treatment planning software; orthodontic bracket systems and lab products; endodontic systems and related consumables; restorative materials and instruments; infection prevention products; digital imaging systems and software; air and electric powered handpieces, and consumables; and treatment units. Its Environmental & Applied Solutions segment offers instrumentation, services, and disinfection systems to analyze, treat, and manage water in residential, commercial, industrial, and natural resource applications. This segment also provides equipment, software, services, and consumables for packaging, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is headquartered in Washington, the District of Columbia.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Revvity forecasts 2026 profit, revenue above estimates after blowout fourth quarter

2026-02-02
Feb 2 (Reuters) - Medical equipment maker Revvity handily beat fourth-quarter estimates and forecast 2026 revenue and profit above Wall Street expectations on Monday, betting on continued strength in

Danaher Invests In Automata To Deepen AI Driven Lab Workflows

2026-01-31
Danaher (NYSE:DHR) has entered an investment partnership with Automata, an AI ready lab automation company. The collaboration focuses on combining Automata's automation systems with Danaher's instruments, reagents, and software. The goal is to offer end to end, AI driven lab solutions that support faster scientific workflows and research. For you as an investor, this move sits at the intersection of life sciences and automation, two areas getting a lot of attention as labs look to scale...

Danaher Stock Plunge Does Not Represent A Good Entry Point

2026-01-30
Danaher (DHR) stock is a "Hold" as GAAP missed in the most recent quarter while valuation remains high. Here's what investors need to know.

Automata Raises $45M Series C to Build the Operating System for AI-Ready Labs

2026-01-29
LONDON, January 29, 2026--Automata, the lab automation company building fully integrated, AI-ready platforms for life sciences, today announced the close of a $45 million Series C funding round led by Dimension with participation from Danaher Ventures, Tru Arrow Partners, Octopus Ventures, Entrepreneurs First, and others. The round also includes a strategic investment partnership with Danaher Corporation, with Murali Venkatesan Ph.D., Global Head of Danaher Ventures and Vice President of Science

DHR Q4 Deep Dive: Bioprocessing and Diagnostics Drive Steady Performance Amid Muted End Markets

2026-01-29
Diversified science and technology company Danaher (NYSE:DHR) met Wall Streets revenue expectations in Q4 CY2025, with sales up 4.6% year on year to $6.84 billion. Its non-GAAP profit of $2.23 per share was 1.8% above analysts’ consensus estimates.

Danaher annual profit declines but sales improve on stronger quarter

2026-01-29

Danaher Corp (DHR) Q4 2025 Earnings Call Highlights: Strong Finish with Robust Free Cash Flow ...

2026-01-28
Danaher Corp (DHR) wraps up 2025 with impressive financial performance, despite challenges in the Life Sciences segment and macroeconomic pressures.

Danaher Q4 Earnings Beat Estimates, Life Sciences Sales Up Y/Y

2026-01-28
DHR beats Q4 estimates as sales rise 4.5%, driven by strength across Life Sciences, Diagnostics and Biotech, and issued upbeat 2026 earnings guidance.

Danaher Q4 Earnings Call Highlights

2026-01-28
Danaher (NYSE:DHR) closed 2025 with what management described as a “strong finish” and better-than-expected performance across its portfolio, driven by continued strength in bioprocessing and improving momentum in diagnostics and life sciences. On the company’s fourth-quarter earnings call, Presiden

Danaher (DHR) Q4 2025 Earnings Call Transcript

2026-01-28
With us today are Rainer Blair, our President and Chief Executive Officer, and Matt McGrew, our Executive Vice President and Chief Financial Officer. With that, I would like to turn the call over to Rainer.